AI-driven medtech startup Brainomix has secured £14 million ($18 million) in fresh Series C funding to supercharge the expansion of its cutting-edge imaging technology. The investment will accelerate the company’s efforts in transforming stroke diagnosis and lung fibrosis treatment through artificial intelligence.
With this latest round, Brainomix’s total funding now stands at £44 million ($57 million). Long-standing backers Parkwalk Advisors—the UK’s largest growth EIS fund manager—and Boehringer Ingelheim Venture Fund (BIVF) led the round. They were joined by new investor Hostplus, an Australian superannuation fund with over AUD $120 billion under management, through the IP Group Hostplus Innovation Fund. LifeSci Capital also participated.
The fresh capital will fuel Brainomix’s research and clinical validation studies, reinforcing the effectiveness of its AI-powered diagnostic solutions.
Speed is critical when treating stroke patients. Every minute saved can protect brain function and improve recovery. That’s where Brainomix steps in. Its flagship product, Brainomix 360 Stroke, uses AI to instantly analyze brain scans, empowering doctors to make faster, life-saving treatment decisions.
Thanks to this technology, hospitals have reported a 50% boost in the number of stroke patients receiving mechanical thrombectomy—a complex yet vital procedure that drastically reduces disability and enhances recovery.
Brainomix was born out of the University of Oxford, co-founded by Dr. Michalis Papadakis and Professor Alastair Buchan. Dr. Papadakis, who leads the company as CEO, holds a PhD in neuroscience from UCL and previously ran Oxford’s preclinical stroke lab. His partner, Professor Buchan, developed the ASPECTS scoring system, a globally recognized method for assessing CT brain scans in stroke patients.
Together, their combined experience has positioned Brainomix as a trailblazer in AI-led stroke diagnosis.
Despite advances in stroke treatment, nearly 80% of eligible patients miss out—often because primary stroke centers lack specialized neuroradiologists. Complex brain scans can easily overwhelm non-specialist teams, leading to costly delays or misdiagnoses.
Brainomix’s AI solution aims to fix that. By delivering fast, accurate analysis of brain CT scans, its platform eliminates bottlenecks, cuts down human error, and ensures patients get the right treatment—fast.
Armed with the new funding, Brainomix is setting its sights on the US market. The company has already secured ten FDA clearances and plans to expand its product range into new therapeutic areas.
With over 75 team members, Brainomix will grow its Oxford headquarters and boost its global presence. The company is hiring specialists in AI development, regulatory affairs, and business growth to strengthen its position in medical imaging.
Beyond stroke care, Brainomix is tackling another complex condition—lung fibrosis. Its Brainomix 360 e-Lung platform, already FDA-approved, leverages AI to predict disease progression and guide treatment decisions. The company is working closely with Boehringer Ingelheim, a leading player in lung fibrosis treatment, to validate the technology in real-world settings.
This partnership aims to improve early identification and access to therapies for patients battling progressive lung fibrosis—a disease notorious for its poor prognosis and diagnostic challenges.
While Brainomix faces competition from US heavyweights like RapidAI and Viz.ai in stroke imaging, it dominates the European market. Its solutions are widely used across Hungary, Wales, and the majority of stroke units in England, demonstrating strong trust and adoption by healthcare providers.
In lung fibrosis, where most AI tools are still confined to research labs, Brainomix is already pushing for clinical adoption—setting the stage for expansion across other critical disease areas.
Dr. Papadakis shared his excitement about the milestone, saying, “We’re grateful to all our investors for believing in our mission. Their support enables us to scale our impact in stroke and lung fibrosis care, improve patient outcomes, and expand into the US market.”
John Pearson, Chief Investment Officer at Parkwalk, emphasized the broader significance of Brainomix’s work: “AI-powered healthcare platforms like Brainomix’s have immense potential to transform diagnosis and treatment. Their imaging technology is delivering societal impact and strong returns, and we’re proud to continue supporting them.”
Echoing that sentiment, Dr. Oliver Reuss, Board Director at Brainomix and Investment Manager at BIVF, added, “Brainomix has an outstanding record of bringing AI solutions to real-world stroke care. Now, they’re doing the same in lung fibrosis—a disease area in desperate need of innovation.”
As Brainomix continues its expansion, the company remains laser-focused on making AI-driven imaging a global standard in healthcare, bridging the gap between advanced technology and life-saving clinical decisions.
